SG11201407752YA - Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof - Google Patents
Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereofInfo
- Publication number
- SG11201407752YA SG11201407752YA SG11201407752YA SG11201407752YA SG11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA SG 11201407752Y A SG11201407752Y A SG 11201407752YA
- Authority
- SG
- Singapore
- Prior art keywords
- shanghai
- lllll
- pyrrolo
- triazine compound
- llll
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210177980.3A CN103450204B (zh) | 2012-05-31 | 2012-05-31 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| PCT/CN2013/074559 WO2013177983A1 (zh) | 2012-05-31 | 2013-04-23 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407752YA true SG11201407752YA (en) | 2015-01-29 |
Family
ID=49672377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407752YA SG11201407752YA (en) | 2012-05-31 | 2013-04-23 | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9447101B2 (es) |
| EP (1) | EP2857403B1 (es) |
| JP (1) | JP6067107B2 (es) |
| KR (1) | KR101824299B1 (es) |
| CN (1) | CN103450204B (es) |
| AU (1) | AU2013270326B2 (es) |
| BR (1) | BR112014029708B1 (es) |
| CA (1) | CA2874062C (es) |
| ES (1) | ES2703934T3 (es) |
| HK (1) | HK1203499A1 (es) |
| MX (1) | MX359207B (es) |
| RU (1) | RU2589053C1 (es) |
| SG (1) | SG11201407752YA (es) |
| WO (1) | WO2013177983A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| US9447105B2 (en) | 2013-01-24 | 2016-09-20 | Council Of Scientific & Industrial Research | Triazine compounds and a process for preparation thereof |
| WO2016064958A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| WO2016064957A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US10292985B2 (en) * | 2015-08-31 | 2019-05-21 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
| CA3028822C (en) * | 2016-06-25 | 2021-06-22 | Suzhou Kintor Pharmaceuticals, Inc. | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof |
| CN109111447A (zh) | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| CN111247150B (zh) * | 2017-08-15 | 2022-11-08 | 石药集团中奇制药技术（石家庄）有限公司 | Fgfr抑制剂及其医药用途 |
| GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| MX2022003217A (es) | 2019-09-19 | 2022-06-29 | Totus Medicines Inc | Conjugados terapeuticos. |
| CN112851563A (zh) * | 2020-12-30 | 2021-05-28 | 安徽金鼎医药股份有限公司 | N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺 |
| WO2023035614A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 包含PI3Kα抑制剂的药物组合 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| TW200635927A (en) | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| US7232901B2 (en) | 2005-07-01 | 2007-06-19 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP2041138B1 (en) | 2006-07-07 | 2014-06-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8022205B2 (en) * | 2006-08-08 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as PI3K inhibitor and use thereof |
| PE20081679A1 (es) * | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| WO2008083398A2 (en) | 2007-01-02 | 2008-07-10 | Bristol-Myers Squibb Company | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate |
| JP5319659B2 (ja) | 2007-04-18 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8129371B2 (en) * | 2007-10-16 | 2012-03-06 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors |
| TW200938201A (en) * | 2008-02-07 | 2009-09-16 | Chugai Pharmaceutical Co Ltd | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof |
| WO2010002954A1 (en) * | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| WO2010002472A1 (en) | 2008-07-02 | 2010-01-07 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| EP2396315B1 (en) * | 2009-02-13 | 2016-08-31 | UCB Biopharma SPRL | Quinoline derivatives as pi3k kinase inhibitors |
| EA022629B1 (ru) * | 2009-04-16 | 2016-02-29 | Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii | Имидазопираны для применения в качестве ингибиторов киназ |
| WO2011089400A1 (en) * | 2010-01-22 | 2011-07-28 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Inhibitors of pi3 kinase |
| WO2011141713A1 (en) * | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| CN102675323B (zh) * | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
-
2012
- 2012-05-31 CN CN201210177980.3A patent/CN103450204B/zh active Active
-
2013
- 2013-04-23 SG SG11201407752YA patent/SG11201407752YA/en unknown
- 2013-04-23 JP JP2015514329A patent/JP6067107B2/ja active Active
- 2013-04-23 RU RU2014147863/04A patent/RU2589053C1/ru active
- 2013-04-23 KR KR1020147033824A patent/KR101824299B1/ko active IP Right Grant
- 2013-04-23 CA CA2874062A patent/CA2874062C/en active Active
- 2013-04-23 ES ES13798006T patent/ES2703934T3/es active Active
- 2013-04-23 AU AU2013270326A patent/AU2013270326B2/en active Active
- 2013-04-23 US US14/403,014 patent/US9447101B2/en active Active
- 2013-04-23 MX MX2014014622A patent/MX359207B/es active IP Right Grant
- 2013-04-23 WO PCT/CN2013/074559 patent/WO2013177983A1/zh active Application Filing
- 2013-04-23 EP EP13798006.6A patent/EP2857403B1/en active Active
- 2013-04-23 BR BR112014029708-8A patent/BR112014029708B1/pt active IP Right Grant
-
2015
- 2015-04-27 HK HK15104065.5A patent/HK1203499A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103450204B (zh) | 2016-08-17 |
| EP2857403A4 (en) | 2015-10-21 |
| BR112014029708B1 (pt) | 2023-05-02 |
| CA2874062C (en) | 2015-09-22 |
| BR112014029708A2 (pt) | 2017-06-27 |
| BR112014029708A8 (pt) | 2021-09-08 |
| MX359207B (es) | 2018-09-19 |
| EP2857403B1 (en) | 2018-10-10 |
| JP6067107B2 (ja) | 2017-01-25 |
| EP2857403A1 (en) | 2015-04-08 |
| MX2014014622A (es) | 2015-08-10 |
| AU2013270326A1 (en) | 2014-12-18 |
| RU2589053C1 (ru) | 2016-07-10 |
| HK1203499A1 (en) | 2015-10-30 |
| ES2703934T3 (es) | 2019-03-13 |
| WO2013177983A1 (zh) | 2013-12-05 |
| KR101824299B1 (ko) | 2018-03-14 |
| AU2013270326B2 (en) | 2016-07-14 |
| US20150141644A1 (en) | 2015-05-21 |
| CA2874062A1 (en) | 2013-12-05 |
| CN103450204A (zh) | 2013-12-18 |
| KR20150009565A (ko) | 2015-01-26 |
| JP2015518010A (ja) | 2015-06-25 |
| US9447101B2 (en) | 2016-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407752YA (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof | |
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201406775UA (en) | Injectable formulation | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |